Isosceles Pharmaceuticals recently won a 2020 Coastal Entrepreneur Award (CEA) for the Biotechnology category. The industry accolades – presented by the Greater Wilmington Business Journal and The Center for Innovation and Entrepreneurship (CIE) at the University of North Carolina Wilmington – celebrate rising ventures in the Cape Fear region.
“Our entire team is honored to be among this great group of visionary businesses and leaders,” said Brett Lanier, president of Isosceles Pharmaceuticals. "As an innovator in non-opioid pain relief, Isosceles is focused on the large, unmet need for alternatives to addictive pain therapeutics to stem the opioid crisis in our country – especially in Wilmington. Isosceles is capitalizing on the availability of an FDA-approved drug master file for synthetic Cannabidiol and is pursuing FDA approval for several delivery methods that will improve bioavailability and mitigate liver toxicity associated with oral delivery.”
This marks the 12th annual CEA, with Isosceles Pharmaceuticals receiving the honor in its first year. Winners are selected not only by their fast growth, but potential to make a significant regional impact, according to a press release issued by organizers.
Isosceles Pharmaceuticals was featured – along with other winners – in a special section of the Greater Wilmington Business Journal. A celebratory event will take place later in 2020. Isosceles Pharmaceuticals currently is developing the delivery of synthetic CBD through an IV and a transdermal skin patch for pain relief. It’s designed to provide healthcare with a safer, non-addictive and effective alternative to opioid treatment.
"We look forward to FDA responses to our regulatory filings,” Lanier said. “While we are confident that our products will make a significant impact at global level, it’s an absolute thrill to be recognized for this effort right here in our own backyard of North Carolina.”